BIOLASE, Inc.

Equities

BIOL

US0909117022

Advanced Medical Equipment & Technology

Market Closed - OTC Markets Other stock markets 03:28:31 2024-07-12 pm EDT			5-day change	1st Jan Change
0.082 ^USD	-8.89%		-8.89%	-92.69%

Jun. 24	BIOLASE, Inc.(NasdaqCM:BIOL) dropped from S&P TMI Index	CI
Jun. 19	BIOLASE, Inc.(OTCPK:BIOL) dropped from NASDAQ Composite Index	CI

BIOLASE Announces Agreement With DSO Dental Care Alliance To Expand Laser Adoption In Dental Offices Across The United States

January 12, 2021 at 09:00 am EST

BIOLASE, Inc. announced an agreement with Dental Care Alliance (DCA) to expand laser adoption and hands-on training programs in targeted geographies. The Company expects the agreement to lead to a rollout across all DCA offices in 2021.

Latest news about BIOLASE, Inc.

BIOLASE, Inc.(NasdaqCM:BIOL) dropped from S&P TMI Index	Jun. 23	CI
BIOLASE, Inc.(OTCPK:BIOL) dropped from NASDAQ Composite Index	Jun. 18	CI
Biolase Gets Delisting Notification From Nasdaq; Shares Sink After Hours	Jun. 18	MT
Wall Street Set to Open Flat Tuesday as Key Inflation Gauge Rises More Than Expected	May. 14	MT
Top Premarket Decliners	May. 14	MT
BIOLASE, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Transcript : BIOLASE, Inc., Q1 2024 Earnings Call, May 13, 2024	May. 13
Earnings Flash (BIOL) BIOLASE Posts Q1 Revenue $10.1M, vs. Street Est of $10M	May. 13	MT
BIOLASE, Inc. Reiterates Earnings Guidance for the Full-Year of 2024	May. 13	CI
Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating	Apr. 01	MT
Wall Street Set to Open Marginally Lower Friday Following Powell Speech, After Hitting Record Highs Thursday	Mar. 22	MT
US Stock Futures Flat Ahead of Powell Speech After Reaching Record Highs on Thursday	Mar. 22	MT
Top Premarket Gainers	Mar. 22	MT
Transcript : BIOLASE, Inc., Q4 2023 Earnings Call, Mar 21, 2024	Mar. 21
BIOLASE, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024	Mar. 21	CI
BIOLASE, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 21	CI
Biolase Prices $7 Million Public Offering	Feb. 13	MT
BIOLASE, Inc. Provides Earnings Guidance for the Full-Year 2023	Jan. 29	CI
BIOLASE, Inc. Provides Earnings Guidance for the Year 2024	Jan. 29	CI
Dr. Carol Gomez Summerhays Intends to Resign as Member of the Board of Directors of Biolase, Inc	Dec. 29	CI
BIOLASE, Inc. Successfully Concludes Waterlase iPlus All Tissue Laser Trial	Dec. 12	CI
Biolase, Inc. Enters into the Eleventh Amendment to Credit Agreement with SWK Funding LLC	Nov. 17	CI
BIOLASE, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Transcript : BIOLASE, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Earnings Flash (BIOL) BIOLASE Reports Q3 Revenue $10.9M, vs. Street Est of $13.2M	Nov. 09	MT

Chart BIOLASE, Inc.

Duration

Period

More charts

Company Profile

BIOLASE, Inc. is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company's systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. It offers two categories of laser system products: Waterlase (all-tissue) systems and diode (soft-tissue) systems. The Company's all-tissue Waterlase dental laser systems consist of its flagship Waterlase iPlus, Waterlase Express, and Waterlase MDX. Its soft tissue diode laser systems consist of the Epic X, Epic Hygiene, Epic Q, and Epic 10 diode lasers that perform soft tissue, hygiene, cosmetic procedures, teeth whitening, and provide temporary pain relief. Epic X, and Epic 10 systems feature its 940 nanometer wavelength with patented pulse technology called ComfortPulse.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for BIOLASE, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.082 USD

Average target price

3.5 USD

Spread / Average Target

+4,168.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
BIOLASE, INC.	-92.69%	2.74M
THERMO FISHER SCIENTIFIC	+3.26%	209B
DANAHER CORPORATION	+6.55%	183B
INTUITIVE SURGICAL, INC.	+31.66%	158B
BOSTON SCIENTIFIC CORPORATION	+34.32%	114B
SIEMENS HEALTHINEERS AG	+5.13%	67.29B
EDWARDS LIFESCIENCES CORPORATION	+19.33%	54.83B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-3.30%	46.88B
AGILENT TECHNOLOGIES, INC.	-4.84%	38.58B
GE HEALTHCARE TECHNOLOGIES INC.	+3.83%	36.65B

Other Advanced Medical Equipment & Technology